Metagenomi, Inc.
MGX
$1.73
$0.074.22%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 45.26M | 52.30M | 55.08M | 55.93M | 47.26M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 45.26M | 52.30M | 55.08M | 55.93M | 47.26M |
| Cost of Revenue | 102.88M | 109.18M | 110.77M | 111.35M | 105.71M |
| Gross Profit | -57.62M | -56.88M | -55.69M | -55.42M | -58.45M |
| SG&A Expenses | 30.07M | 32.02M | 32.78M | 33.06M | 31.13M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 132.95M | 141.20M | 143.55M | 144.42M | 136.84M |
| Operating Income | -87.69M | -88.90M | -88.47M | -88.49M | -89.59M |
| Income Before Tax | -83.36M | -83.57M | -75.53M | -73.27M | -71.44M |
| Income Tax Expenses | -5.42M | -5.51M | -1.58M | 1.73M | 5.83M |
| Earnings from Continuing Operations | -77.95 | -78.06 | -73.95 | -75.00 | -77.27 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -77.95M | -78.06M | -73.95M | -75.00M | -77.27M |
| EBIT | -87.69M | -88.90M | -88.47M | -88.49M | -89.59M |
| EBITDA | -82.20M | -83.49M | -83.33M | -83.55M | -84.95M |
| EPS Basic | -2.11 | -2.62 | -7.66 | -12.97 | -14.21 |
| Normalized Basic EPS | -1.25 | -1.58 | -4.33 | -7.42 | -8.23 |
| EPS Diluted | -2.11 | -2.62 | -7.66 | -12.97 | -14.21 |
| Normalized Diluted EPS | -1.25 | -1.58 | -4.33 | -7.42 | -8.23 |
| Average Basic Shares Outstanding | 147.72M | 131.84M | 97.93M | 64.57M | 36.44M |
| Average Diluted Shares Outstanding | 147.72M | 131.84M | 97.93M | 64.57M | 36.44M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |